Supervivencia a los tres años del diagnóstico de 72 casos con tuberculosis y SIDA en la era pre-TARVAE en Cuba / Survival of patients three years after the diagnosis of tuberculosis and AIDS in Cuba during pre-HAART era

RESUMEN

Fundamento Hay más de 40 millones de afectados en el mundo por el VIH/SIDA; han muerto alrededor de 20 millones de personas desde los inicios de la epidemia. Hay mayores tasas de mortalidad y menor supervivencia en los enfermos con tuberculosis (TB) e infección por el VIH-I. Particularmente, en Cuba no existen estudios previos que aborden la supervivencia en individuos coinfectados por VIH/TB. Métodos: Estudio observacional de una serie de 72 casos con TB y SIDA antes de generalizada la terapia antirretroviral de alta eficacia (TARVAE). Se describen variables clínicas e inmunológicas que se relacionan con la supervivencia a los tres años del diagnóstico de la TB y con el riesgo de muerte. Utilizamos el método de Kaplan-Meier y de riesgos proporcionales de Cox. Resultados: El 69.4% de los enfermos habían fallecido a los tres años del diagnóstico de la TB. La media del recuento de LTCD4+ resultó significativamente inferior en los muertos 126 células por mm³ (p < 0.0001). El 44.4% de los casos cumplió los criterios de muerte por TB. La mediana de supervivencia global fue de 10 meses. Tener LTCD4 + < a 200 células y padecer candidiasis profunda previo a la TB, se asoció independientemente con el riesgo de muerte. Conclusiones: En ausencia de TARVAE, las infecciones oportunistas y el deterioro inmunológico en los individuos con SIDA y TB se relacionaron con un mayor riesgo de muerte.

ABSTRACT

Background: Infection due to HIV/AIDS affects more than 40 million people worldwide; around 20 million have succumbed since the epidemy began. There are higher mortality rates and shortened survival in those affected by tuberculosis (TB) and HIV-I. In Cuba, there are no previous studies regarding the survival of patients coinfected by HIV/TB. Methods: Observational study of a series of 72 cases infected by TB and AIDS before the widespread use of highly active anti-retroviral therapy (HAART); we describe the clinical and immunological variables associated to three year survival from the diagnosis of TB/AIDS and to the risk of death. Survival analyses were done by the Kaplan-Meier method and the log-rank test to determine the survival function according to categories of the variables included. Cox's proportional hazards was used to determine the independent association of each variable with the risk of death. Results: 51.4% of patients were dead one year and 69.4%, three years after the diagnosis of TB. Mean CD4+T lymphocyte counts were significantly lower in the deceased, 126 cells/mm³ (p < 0.0001); 44.4% fulfilled the criteria of death caused by TB. Mean survival was 10 months; survival was higher in those patients with TB as the first condition indicative of AIDS, in those who were not AIDS before TB, in those not having previous deep candidiasis, when CD4 + T lymphocyte counts > 200/mm³, in those with a reactive tuberculin skin test and when smears from sputum were negative to acid fast bacilli. The risk of death was independently associated to CD4 + T lymphocyte counts < 200/mm³, and having deep candidiasis before TB. Conclusions: In the absence of HA ART, opportunistic infections and immunologic impairment in patients with AIDS and TB are related to lower survival rates and increased risk of death.